Iron in Multiple Myeloma
Authors:
- Tracy R. Daniels-WellsTDTracy R. Daniels-Wells
- Alan LlichtensteinALAlan Llichtenstein
- 1 January 2013
- journal article
- review article
- Published by Begell House Inc. Publishers in Critical Reviews™ in Oncogenesis
- Vol. 18 (5) , 449-461
Abstract
Multiple myeloma is a non-curable B-cell malignancy in which iron metabolism plays an important role. Patients with this disorder almost universally suffer from clinically significant anemia, which is often symptomatic, and which is due to impaired iron utilization. Recent studies have indicated that the proximal cause of dysregulated iron metabolism and anemia in these patients is cytokine-induced upregulation of hepcidin expression. Malignant myeloma cells are dependent on an increased influx of iron, and therapeutic efforts are being made to target this requirement. The studies detailing the characteristics and biochemical abnormalities in iron metabolism causing anemia and the initial attempts to target iron therapeutically are described in this review.Keywords
This publication has 72 references indexed in Scilit:
- Medical Applications and Toxicities of Gallium CompoundsInternational Journal of Environmental Research and Public Health, 2010
- Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cellsAmerican Journal of Hematology, 2008
- Phenotypic and Functional Reversal Within the Early Human Hematopoietic CompartmentStem Cells, 2008
- Regulation of hepcidin transcription by interleukin-1 and interleukin-6Proceedings of the National Academy of Sciences, 2005
- Anemia in multiple myeloma.2004
- Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturationEuropean Journal of Clinical Investigation, 2002
- Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myelomaBlood, 2002
- Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review.2001
- Clinical results of recombinant erythropoietin in transfusion‐dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesisEuropean Journal of Haematology, 1997
- Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin productionBritish Journal of Haematology, 1992